Literature DB >> 22290487

Mutation screening of RET proto-oncogene in a family with medullary thyroid carcinoma, marfanoid habitus and pheochromocytoma; from clinically MEN2B to genetically MEN2A syndrome.

Shirin Hasani-Ranjbar1, Mahsa M Amoli.   

Abstract

Entities:  

Year:  2012        PMID： 22290487     DOI： 10.1007/s12020-012-9610-6

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


× No keyword cloud information.
  5 in total

1.  Overexpression of genes involved in miRNA biogenesis in medullary thyroid carcinomas with RET mutation.

Authors:  Cinzia Puppin; Cosimo Durante; Marialuisa Sponziello; Antonella Verrienti; Valeria Pecce; Elisa Lavarone; Federica Baldan; Antonio Francesco Campese; Amelie Boichard; Ludovic Lacroix; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Endocrine       Date:  2014-02-26       Impact factor: 3.633

2.  Changing pattern of pheochromocytoma and paraganglioma in a stable UK population.

Authors:  I T Cvasciuc; S Gull; R Oprean; K H Lim; F Eatock
Journal:  Acta Endocrinol (Buchar)       Date:  2020 Jan-Mar       Impact factor: 0.877

Review 3.  Metachronous appearance of second malignancies in medullary thyroid carcinoma (MTC) patients: a diagnostic challenge and brief review of the literature.

Authors:  Maria Alevizaki; Elena Kyratzoglou; Aristoteles Bamias; Marinella Tzanela; Meletios A Dimopoulos; Katerina Saltiki
Journal:  Endocrine       Date:  2013-04-23       Impact factor: 3.633

Review 4.  Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?

Authors:  Krzysztof Kaliszewski; Maksymilian Ludwig; Bartłomiej Ludwig; Agnieszka Mikuła; Maria Greniuk; Jerzy Rudnicki
Journal:  Cancers (Basel)       Date:  2022-07-27       Impact factor: 6.575

Review 5.  Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.

Authors:  Cosimo Durante; Alessandra Paciaroni; Katia Plasmati; Fabiana Trulli; Sebastiano Filetti
Journal:  Endocrine       Date:  2013-04-14       Impact factor: 3.633
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.